Management of Non-BPPV Peripheral Vertigo

Medication Management

• Vestibular suppressant medications should be used for short-term management of severe symptoms rather than as definitive treatment, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 1, 2
• Meclizine is the most commonly used antihistamine for peripheral vertigo, working by suppressing the central emetic center, and should be used primarily as-needed (PRN) rather than on a scheduled basis to avoid interfering with vestibular compensation 2
• Benzodiazepines may be used for short-term management of severe vertigo symptoms and can help with psychological anxiety secondary to vertigo, according to the American Academy of Otolaryngology-Head and Neck Surgery 3
• Prochlorperazine can be used for short-term management of severe nausea or vomiting associated with vertigo, but is not recommended as primary treatment for the vertigo itself 1

Important Cautions and Considerations

• Vestibular suppressant medications can cause significant side effects including drowsiness, cognitive deficits, and interference with driving, and are a significant independent risk factor for falls, especially in elderly patients, as noted by the American Academy of Otolaryngology-Head and Neck Surgery 1, 3
• Long-term use of vestibular suppressant medications can interfere with central compensation in peripheral vestibular conditions 2

Treatment and Follow-up

• For severe nausea/vomiting, consider adding prochlorperazine for short-term management, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 1
• For anxiety component, consider short-term benzodiazepine use, according to the American Academy of Otolaryngology-Head and Neck Surgery 3
• Reassess patients within 1 month after initial treatment to document resolution or persistence of symptoms, and transition from medication to vestibular rehabilitation when appropriate to promote long-term recovery, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 4, 5

Vertigo Management with Meclizine

Efficacy Considerations

• For Ménière's disease attacks, the American Academy of Otolaryngology-Head and Neck Surgery recommends offering a limited course of vestibular suppressants only during acute attacks 6, 7

Side Effect Profiles

• Anticholinergic side effects can occur with both meclizine and dimenhydrinate, but may be less pronounced with meclizine, according to the American Academy of Otolaryngology-Head and Neck Surgery 7

Lifestyle Modifications

• Patients should be educated on dietary and lifestyle modifications that may reduce or prevent vertigo symptoms, including limiting salt/sodium intake, avoiding excessive caffeine, alcohol, and nicotine, and managing stress appropriately, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 7
• Adequate hydration, regular exercise, and sufficient sleep can help manage vertigo symptoms, according to the American Academy of Otolaryngology-Head and Neck Surgery 7

Management of Vertigo Symptoms

Recommended Usage Guidelines

• The American Academy of Family Physicians recommends a typical dosage of 5-10 mg orally or intravenously, with a maximum of three doses per 24 hours 8
• The American Academy of Otolaryngology-Head and Neck Surgery suggests that dietary and lifestyle modifications should be implemented alongside medication management for better symptom control 9
• Prochlorperazine should be used with caution in patients with CNS depression or those using adrenergic blockers, as recommended by the American Academy of Family Physicians 8

Special Considerations for Different Types of Vertigo

Ménière's Disease

• For Ménière's disease attacks, the American Academy of Otolaryngology-Head and Neck Surgery recommends that vestibular suppressants like prochlorperazine should only be offered during acute attacks, not as continuous therapy 9

Lifestyle Modifications

• The American Academy of Otolaryngology-Head and Neck Surgery suggests that lifestyle modifications including limiting salt/sodium intake, avoiding excessive caffeine, alcohol, and nicotine, and managing stress appropriately can help reduce vertigo symptoms 9

Management of Vertigo with Medications

Medication Selection by Clinical Context

• The American Academy of Otolaryngology-Head and Neck Surgery recommends a limited course of vestibular suppressants, such as meclizine or benzodiazepines, only during acute attacks of Ménière's disease, not as continuous therapy 10
• Betahistine showed no significant benefit over placebo in reducing vertigo attack frequency over 9 months in patients with Ménière's disease, according to the 2020 BEMED trial 10

Treatment Approach

• Long-term management of Ménière's disease relies on dietary modifications, such as salt restriction, and diuretics rather than vestibular suppressants 10

Vertigo Management with Prochlorperazine and Cinnarizine

Clinical Considerations

• The American Academy of Family Physicians recommends prochlorperazine for immediate symptom control in emergency/acute settings, with a typical dosing of 5-10 mg orally or intravenously, maximum three doses per 24 hours, for patients with severe nausea/vomiting, but with caution in patients with psychiatric history, due to the risk of extrapyramidal symptoms 11
• The American family physician guidelines suggest that prochlorperazine is contraindicated in patients with CNS depression or concurrent use of adrenergic blockers, and in patients with severe hypotension, as it can worsen hemodynamic instability 11, 12
• Patients with severe hypotension should avoid prochlorperazine, as it can exacerbate hypotensive episodes, according to the Genetics in Medicine journal 12

Contraindications and Precautions

• The American family physician recommends avoiding prochlorperazine in patients with psychiatric history, due to the risk of extrapyramidal symptoms, with a strength of evidence based on clinical experience 11

Acute Vestibular Suppressant Options

Introduction to Vestibular Suppressant Use

• The American Academy of Otolaryngology recommends offering a limited course of vestibular suppressants, such as meclizine 25-100 mg daily or benzodiazepines, for short-term symptom control during severe acute vestibular attacks, typically for no more than 3-5 days, as prolonged use interferes with central vestibular compensation and increases fall risk 13

Critical Cautions and Contraindications

• Vestibular suppressants should not be used for chronic or ongoing management, but only during acute attacks, as stated by the American Academy of Otolaryngology, and should be withdrawn as soon as possible, preferably after the first several days 13
• The American Academy of Otolaryngology explicitly recommends against using vestibular suppressants during vestibular rehabilitation, as medications impede the compensation process 14

Special Considerations

• For patients with Ménière's Disease, vestibular suppressants should only be offered during acute attacks, not as continuous therapy, as recommended by the American Academy of Otolaryngology 13

What to Avoid

• The European Heart Journal recommends against using sotalol or lidocaine for acute vestibular symptoms, as these are downgraded or not recommended 15
• The European Heart Journal also recommends against using amiodarone or digoxin for acute management, as these are no longer recommended 15

Management of Severe Vertigo and Nausea in Labyrinthitis

Introduction to Treatment Options

• The American Academy of Otolaryngology-Head and Neck Surgery recommends proclorperazina for the short-term management of severe nausea and vomiting associated with vertigo, due to its potent antiemetic effect on both central and peripheral dopaminergic receptors 16

Diagnostic Considerations

• Labyrinthitis is characterized by prolonged severe vertigo (>24 hours), profound hearing loss, intense nausea, and vomiting, requiring more aggressive vestibular suppression in the acute phase 17

Treatment Guidelines

• The American Academy of Otolaryngology-Head and Neck Surgery guidelines suggest proclorperazina as the preferred treatment for severe nausea and vomiting in vertigo, with a recommended dosage of 5-10 mg orally or intramuscularly every 6 hours, for a maximum of 3 doses in 24 hours 16
• Proclorperazina has been shown to be more effective and better tolerated than metoclopramide in the treatment of vertigo, with less sedation and somnolence, and higher bioavailability 17

Contraindications and Precautions

• Metoclopramide is not recommended as a primary treatment for vertigo, as it does not address the underlying cause and has lower efficacy due to reduced oral bioavailability and compromised absorption in the presence of vomiting 18, 19, 20, 16

Management of Acute Peripheral Vertigo in Older Adults with Cardiovascular Disease

Medication Considerations

• Older adults with cardiovascular disease are already at increased polypharmacy risk with potential drug-drug interactions, according to the European Society of Cardiology 21, 22
• Age-related pharmacokinetic changes affect drug metabolism, decreasing hepatic blood flow and reducing clearance of drugs like metoprolol, propranolol, diltiazem, and verapamil, as noted by the European Heart Journal 21
• Monitor for drug-drug interactions with cardiovascular medications already prescribed, as recommended by the European Society of Cardiology 21, 22

Fall Risk Management

• Educate patients about postural hypotension before prescribing any vestibular suppressant, as advised by the European Society of Cardiology 22, 23
• Consider deprescribing other medications that contribute to fall risk when adding vestibular suppressants, according to the European Society of Cardiology 22, 23

Diagnostic Considerations

• Verify true vertigo (spinning sensation) vs vague dizziness or presyncope, and rule out central causes, such as stroke, migraine, or CPA tumors, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 24

Treatment Approach

• Review medication list for potential deprescribing opportunities given polypharmacy concerns, as recommended by the European Society of Cardiology 22, 23

Vestibular Rehabilitation in Acute Vestibular Neuritis

Timing and Initiation

• The American Academy of Otolaryngology‑Head and Neck Surgery recommends beginning vestibular rehabilitation exercises as soon as acute symptoms subside, usually within the first week after onset. High‑quality evidence (systematic review of randomized trials) supports this early start. 25

Comparative Efficacy

• Vestibular exercise programs achieve long‑term recovery rates comparable to corticosteroid therapy, with approximately 45 % of patients attaining complete symptom resolution at 12 months. Evidence derives from multiple randomized controlled trials, indicating moderate‑to‑high certainty. [25][26]

Safety Profile

• Across 21 randomized trials, vestibular rehabilitation was not associated with any serious adverse events, demonstrating a high safety margin for this intervention. [25][26]

Delivery Setting

• Current evidence does not favor formal outpatient (supervised) therapy over home‑based exercise programs; both approaches appear similarly effective, reflecting insufficient evidence for superiority. [25][26]
• An initial supervised instruction session followed by home‑based practice has been shown to be cost‑effective, supporting a pragmatic hybrid model. Moderate‑quality evidence underpins this recommendation. [25][26]

Special Populations

• Patients with comorbid conditions that limit mobility or neck movement—such as cervical spinal stenosis, severe rheumatoid arthritis, morbid obesity, or spinal cord injury—may require tailored vestibular rehabilitation protocols to accommodate their specific limitations. Evidence is drawn from subgroup analyses within the same guideline source. [25][27]

Diagnostic Pitfall

• The American Academy of Otolaryngology‑Head and Neck Surgery cautions that repositioning maneuvers effective for benign paroxysmal positional vertigo are ineffective for vestibular neuritis, emphasizing the importance of accurate diagnosis before initiating treatment. Expert consensus provides this guidance. 25

Medication Recommendations and Risks in Acute Vertigo

Medications to Avoid

• Opioids and butalbital should not be used for the management of acute episodic vertigo because they lack proven benefit and carry significant safety concerns. 28

Risks of Vestibular Suppressor Overuse

• Using vestibular suppressants (e.g., meclizine) for more than 10–15 days per month can lead to rebound vertigo symptoms, emphasizing the need to limit their duration to short courses (≤3–5 days) during acute attacks. 28